Introduction {#s0005}
============

Cutaneous melanoma is among the most aggressive and fatal malignancies with a dramatic increase of incidence in the Caucasian population during the last decades [@bb0005]. Remarkably, even small and early primary lesions are able to seed satellite, in-transit, lymph node or even distant metastases [@bb0010]. Once metastasized, prognosis of patients with melanoma is poor, despite the development of new targeted therapies over the last years [@bb0015], [@bb0020]. Hepatic metastasis occurs in 14-20% of cutaneous melanoma and is an important determinant of devastating clinical course [@bb0010], [@bb0025], [@bb0030]. Hence, novel therapeutic options are urgently needed to improve the prognosis of patients suffering from this disease.

Activation of the mammalian target of rapamycin (mTOR) signaling pathway is frequently reported in human cancer [@bb0035]. However, mTOR signaling is mediated *via* two distinct multi-component kinases, mTOR complex 1 (mTORC1) and 2 (mTORC2). The rapamycin-sensitive mTORC1 with its essential subunit RAPTOR (Regulatory-Associated Protein of mTOR) has been extensively studied and mainly regulates protein biosynthesis via S6K1 and 4E-BP [@bb0035]. In contrast, mTORC2 with its crucial component RICTOR (rapamycin-insensitive companion of mTOR) is less well studied. Several lines of evidence indicate that mTORC2/RICTOR acts primarily as a regulator of AGC kinase phosphorylation/activation, particularly AKT^Ser473^ [@bb0035], [@bb0040], [@bb0045]. Functionally, mTORC2 is involved in mediating growth factor signaling, thereby affecting cell survival and cytoskeleton remodeling [@bb0035], [@bb0040]. In cancer, RICTOR overexpression and association with poor prognosis has been found in several tumor entities, including colorectal cancer, hepatocellular carcinoma and pancreatic cancer [@bb0050], [@bb0055], [@bb0060]. With regard to melanoma, Laugier *et al*. showed that the RICTOR locus is frequently amplified and that deregulation of RICTOR is involved in melanoma development *via* PI3K signaling [@bb0065]. Recently, the mTORC2-AKT axis has been connected to metabolic reprogramming in melanoma [@bb0070]. Finally, mTORC2 regulation of AKT-MMP-2/9 pathway by RICTOR has been shown to regulate vasculogenic mimicry in melanoma [@bb0075]. Nonetheless, little is known about the role of RICTOR in melanoma progression and metastasis.

The liver is a major metastasis-susceptible site for multiple malignancies including melanoma. Notably, the majority of patients with hepatic metastasis die from the disease in the absence of efficient treatment [@bb0030], [@bb0080]. Different phases during the development of liver metastasis have been described with several non-cellular and cellular components being involved [@bb0085], [@bb0090], [@bb0095]. Among these, liver specific pericytes, also known as hepatic stellate cells (HSC), have been shown to transdifferentiate into highly proliferative and motile myofibroblasts thereby promoting tumor cell migration, growth and survival [@bb0100]. Particularly, HSC are implicated in stimulation of angiogenesis [@bb0105], suppression of the anti-tumor immune response [@bb0110] and supply of tumor cells with growth factors and cytokines, such as hepatocyte growth factor (HGF) [@bb0115], [@bb0120]. Interestingly, a recent report also shows a reciprocal connection with melanoma cells stimulating proliferation and motility of HSC [@bb0125]. However, the interaction between melanoma cells and HSC is still poorly understood.

In the present study, we assessed the role of mTORC2/RICTOR in hepatic metastasis from melanoma cells *in vitro* and *in vivo* with special emphasis on HSC-melanoma cell interaction. Our results demonstrate that RICTOR depletion causes a significant impairment of tumor cell motility and AKT phosphorylation *in vitro* as well as significantly reduction of metastases formation *in vivo*. Interestingly, RICTOR blockade in melanoma cells also leads to reduced responsiveness to protumorigenic effects of conditioned media (CM) from HSC and HGF. In summary, we provide evidence for mTORC2/RICTOR being an interesting target for anti-neoplastic therapy in melanoma liver metastasis.

Material and Methods {#s0010}
====================

Cell Lines, Culture Conditions and Reagents {#s0015}
-------------------------------------------

Two human melanoma cell lines (MelIM, MelJU) and the murine melanoma cell line B16 were used for the experiments. Expression analysis was performed using normal human epidermal melanocytes (NHEM-I and NHEM-II) in comparison to both human melanoma cell lines (MelIM, MelJU). Furthermore, we used the two human HSC cell lines LX2 cells and HSC^hTERT^. LX2 were generated by spontaneous immortalization in low serum conditions [@bb0130]. HSC^hTERT^ cells are an immortal activated human hepatic stellate cell line generated by ectopic telomerase expression [@bb0135]. All three melanoma cell lines were derived from metastases of malignant melanoma as described before [@bb0140]. MelIM and MelJU cells were cultured in low Glucose (1 g/L) Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum (FCS), while B16 cells, HSC^hTERT^ and LX2 cells were grown in high glucose (4,5 g/L) DMEM supplemented with 10% FCS. All cell lines were maintained at 37°C in a humidified atmosphere with 5% CO~2~. Conditioned media (CM) from HSC lines was generated as previously described [@bb0145]. Human recombinant HGF was obtained from Peprotech (Hamburg, Germany).

In Silico Analysis {#s0020}
------------------

In silico analysis of RICTOR RNA expression levels was performed using a Gene Expression Omnibus (GEO) dataset (GDS1989). OncomineTM cancer microarray database [@bb0150] analysis for gene expressions was performed using the website <https://www.oncomine.org/>.

Immunohistochemical Analysis of RICTOR Expression in Human Melanoma Liver Metastases {#s0025}
------------------------------------------------------------------------------------

All patients were operated and diagnosed at the University Medical Center Freiburg. After diagnosis, tissue specimens collected by the Institute of Surgical Pathology at the University Medical Center Freiburg have been included into the presented study for initial expression analyses of RICTOR. Therefore, a retrospective cohort comprising six patients with hepatic metastasized malignant melanomas has been compiled. Tissue specimens were reviewed through a pathologist from the Tumorbank of the Comprehensive Cancer Center Freiburg. Written informed consent was obtained from each patient before inclusion.

All tissue specimens underwent gross section and were immediately formalin fixed. After formalin fixation and paraffin embedding, 2 μm-thick sections were cut, mounted onto cover slips, dried at 58° Celsius for 48 hours, deparaffinized in xylene and dehydrated with ethanol. Epitope heat demasking was performed for five minutes via an autoclave (pressure 0.8 bar). Slides were stained using the ready to use primary antibodies RICTOR (monoclonal, mouse anti-RICTOR Abcam, Cambridge, UK). Dako REAL™ Link (Santa Clara, CA, USA), biotinylated secondary antibodies, and subsequent incubation with Dako REAL™ streptavidin alkaline phosphatase (Santa Clara, CA, USA) was performed. For visualization, RED chromogen (Santa Clara, CA, USA) was used. Counterstaining was performed with hematoxylin before adding a coverslip.

Suppression of RICTOR Expression {#s0030}
--------------------------------

Due to the lack of specific inhibitors, RNA interference was used to suppress RICTOR expression. MelIM, MelJU and B16 were transiently transfected with two different siRNA sequences targeting human \[(Silencer® Select; s48410 (=RICTOR si1), s226000 (=RICTOR si2)); Invitrogen, Waltham, MA, USA\] or murine \[(Silencer® Select; s95670 (RICTOR si1), s95672 (RICTOR si2)); Invitrogen, Waltham, MA, USA\] RICTOR and scrambled siRNA control \[(Silencer® Select; scrambled siRNA = ctrl. Si); Invitrogen, Waltham, MA, USA\] using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Waltham, MA, USA). Briefly, pre-plated cells were incubated with transfection mixture \[Opti-MEM® (Gibco, Waltham, MA, USA), Lipofectamine 2.5% vol/vol, siRNA 50 nM\] for 6 hours. 48 hours after transfection knock-down efficiency was confirmed by Western blotting and tumor cells were processed for further experiments.

Measurement of Cell Growth {#s0035}
--------------------------

Assessment of *in vitr*o growth upon RICTOR blockade was performed using the MTT \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium\] assay as described [@bb0055], [@bb0155]. Cancer cells transfected with RICTOR siRNA (and respective controls) were seeded into 96-well plates (2x10^3^ cells/well). Cells were grown with medium containing 10% FCS. After 24 and 48 hours, the MTT assay was performed, as described elsewhere [@bb0155]. In addition, effects of RICTOR inhibition on growth of tumor cells *in vitro* were determined in a cell-counting assay as described [@bb0155]. Briefly, 10^5^ cells were seeded into 6-well dishes; after 24 and 48 hours, cells were trypsinised and counted. Finally, cell proliferation was monitored by 5′-bromodeoxyuridine (BrdU) incorporation assay (Roche Diagnostics, Mannheim, Germany). Three thousand cells were cultured for 24 and 48 hours in 96-well plates and stained with BrdU as previously described [@bb0160]. The percentage of cells exhibiting genomic BrdU incorporation was measured by absorbance at 370 nm with Tecan Infinite200 (Tecan, Männedorf, Switzerland). Percentages were calculated relative to ctrl. si.

Analysis of Cell Migration {#s0040}
--------------------------

Migration assays were conducted using modified Boyden chambers with 8 μm filter pore inserts (BD, Heidelberg, Germany), as previously described [@bb0055], [@bb0155]. Briefly, after transfection with RICTOR siRNA, 5×10^4^ cancer cells were suspended in serum-starved medium (1% FCS). HGF (50 ng/ml), CM from HSCs (LX2 and HSC^hTERT^) or 10% FCS served as chemoattractant. After 24 hours, migrated cells were fixed, stained (Diff Quik, Medion Diagnostics, Miami, FL, USA), counted in four random fields and average results were calculated.

Western Blotting {#s0045}
----------------

Western blotting was performed to confirm RICTOR knock-down and to assess its impact on AKT expression/phosphorylation, as described [@bb0055], [@bb0155]. In brief, cells were grown under constitutive conditions or stimulated with either CM from HSC or HGF (50 ng/ml) for 15 minutes after overnight (o/n) serum-starvation. Protein samples (30 μg) were subjected to a denaturating 10% SDS-PAGE. Membranes were sequentially probed with primary antibodies against RICTOR, pAKT^Ser473^, pAKT^Thr308^, and AKT (Cell Signaling, Beverly, MA, USA). PDI (Enzo Life Sciences, Farmingdale, NY, USA) served as a loading control. Antibodies were detected by enhanced chemiluminescence (GE Healthcare Life Sciences, Freiburg, Germany). Finally, densitometry was performed using ImageJ (1.46r; <http://imagej.nih.gov.ij>). Expression of pAKT^Ser473^ was calculated in relation to total AKT.

Mouse Model of Hepatic Metastasis {#s0050}
---------------------------------

To assess the impact of RICTOR inhibition on hepatic metastasis *in vivo*, a syngeneic mouse model was performed as described [@bb0165]. Experiments were approved by the Institutional Animal Care and Use Committee of the University of Regensburg and the regional authorities. In addition, experiments were conducted according to "Guidelines for the Welfare of Animals in Experimental Neoplasia" published by The United Kingdom Coordinating Committee on Cancer Research.

In this model, B16 cells (2.5 x 10^5^ cells) were injected into the spleen of C57BL/6N mice (eight-week old male, Charles River, Sulzfeld, Germany). The experiment was performed with 3 groups \[control, RICTOR si1 (transient transfection with s95670), RICTOR si2 (transient transfection with s95672); 11 animals/group\]. Two RICTOR siRNAs with different sequences were used to avoid off-target effects. 10 days after intrasplenic tumor cell injection, mice were terminated. Upon necropsy, the liver was dissected, weighed and processed for further analyses.

Assessment of Hepatic Tumor Burden {#s0055}
----------------------------------

First, extent of hepatic metastases was evaluated by a macroscopic score (0 = no tumor load (not shown), 1 = low tumor load (only scattered tumor spots visible on the liver surface), 2 = medium tumor load (confluent tumor visible on anterior or posterior surface of the liver), 3 = high tumor load (confluent tumor visible on anterior and posterior surface of the liver), [Figure 2](#f0010){ref-type="fig"}*C*). Additionally, liver weight was determined and used as a surrogate parameter for hepatic tumor burden. To assess the hepatic tumor load more precisely, staining for H&E (Merck 1.09 249.1000 and 1.09 844.1000) using standard protocols for formalin-fixed tissues was performed on 5μm liver sections serially cut at 100μm intervals. Sections were analyzed at 10x magnification with a Zeiss Axioplan 2 microscope under bright-field conditions, and images captured with a Zeiss Axiocam camera using AxioVision 3.0 software as described before [@bb0170]. Total liver area and tumor area were measured using ImageJ and determined as μm^2^. Tumor load was subsequently calculated as percent of total liver area.

Immunohistochemical Assessment of Activated HSC (αSMA) {#s0060}
------------------------------------------------------

To identify active HSC, liver sections were stained for α-smooth muscle actin (αSMA), a known stellate cell marker, as described [@bb0115], [@bb0175]. Briefly, cryosections of liver were fixed in cold acetone and chloroform, washed with PBS and exposed to primary antibody against αSMA (1:200; Abcam, Cambridge, UK) and the secondary antibody AlexaFluor 594 (1:200; Live Technologies, Carlsbad, CA, USA) was applied as described. Hoechst 33342 (1:400, Cell Signaling, Beverly, MA, USA) was used for the nuclear counterstain.

Analysis of HGF mRNA Expression {#s0065}
-------------------------------

RICTOR and HGF mRNA expression was determined in human melanoma cell lines and hepatic stellate cells using quantitative RT-PCR. In addition, mRNA expression of HGF, αSMA, collagen-1α, and RICTOR was determined in liver tissue, as previously described [@bb0055], [@bb0180].

Statistical Analysis {#s0070}
--------------------

Statistical analyses were carried out using SigmaStat (Version 3.0). Results of *in vivo* experiments were analyzed for significant outliers using the Grubb's test ([www.graphpad.com](https://www.graphpad.com){#ir1015}). Tumor-associated variables of *in vivo* experiments were tested for statistical significance using the Mann-Whitney U test for nonparametric data or ANOVA followed by Tukey's multiple comparison tests for more than 2 groups. The two-sided Student's t test was applied for analysis of *in vitro* data. All results are expressed as the mean ± standard error of the mean (SEM).Figure 1Expression of RICTOR in melanoma cells and tissues.(A) Quantitative RT-PCR analysis shows a significant higher RICTOR mRNA expression in human melanoma cell lines MelJU and MelIM compared to normal human epidermal melanocytes (NHEM) (\**P* \< .05 vs. NHEM-I; bars=SE).(B) Gene Expression Omnibus (GEO) dataset analysis (GDS1989) comparing RICTOR mRNA expression in human nevi (benign nevi (n=2), atypical nevi (n=2)), non-metastatic melanoma tissues (n=4) and metastatic melanoma tissues (metastatic growth phase melanoma (n=2) and lymph node metastasis (n=2)). (n.s. non-significant; \**P* \< .05 vs. nevi; bars=SE).(C) RICTOR mRNA levels in the \"tumor center\" (n=9) are significantly lower compared to the \"invasive margin\" (n=9) of melanoma tissues (\**P* \< .05). The data were obtained from the OncomineTM cancer microarray database using the dataset \"Roesch Melanoma\" (n=18 samples).Figure 1Figure 2RICTOR depletion in human and murine melanoma cell lines and its impact on growth and motility *in vitro*.(A, B) Upon transient transfection with two different siRNAs (RICTOR si1, RICTOR si2), RICTOR expression is impaired compared to controls (ctrl. Si = scramble RNA), as determined by Western blotting (A) and densitometry (B).(C) In B16 cells, significant reduction of MTT signal was detected after 24 hours. After 48 hours, a growth inhibitory effect is only observed upon RICTOR si1 (^\#^,\**P* \< .05 vs. ctrl. Si; bars=SEM).(D) BrdU incorporation assay shows no significant anti-proliferative effect of RICTOR knock-down on B16 cells after 24 and 48 hours.(E, F, G) Constitutive tumor cell motility measured by Boyden Chamber assays is significantly decreased upon RICTOR inhibition in MelIM (F), MelJU (G) and B16 melanoma (H) cells lines compared to controls (\**P* \< .05 vs. ctrl. Si; bars=SEM).Figure 2Figure 3Modulation of melanoma metastasis *in vivo* (B16 splenic injection model).(A) Significant reduction of macroscopically visible hepatic tumor load is found in both groups with RICTOR depletion compared to controls. (\**P* \< .05 vs. control; bars=SE).(B) This effect is confirmed with regard to liver weight. (\**P* \< .05 vs. control; bars=SE).(C) Examples for macroscopic stratification of hepatic tumor burden from 0 to 3: 0 = no tumor load (not shown), 1 = low tumor load, 2 = medium tumor load, 3 = high tumor load.(D) Examples of H&E liver sections of mice with intrasplenically injected B16 cells (control cells and two RICTOR siRNA) after 10 days. (bars=1 mm).(E) Percentage of tumor area related to total liver area is significantly lower upon RICTOR depletion compared to controls. (\**P* \< .05 vs. control; bars=SEM).Figure 3

Results {#s0075}
=======

RICTOR Expression in Melanoma Cells and Tissues {#s0080}
-----------------------------------------------

Initially, we analyzed the expression of RICTOR in 2 different human melanoma cell lines (MelIM, MelJU) and found a significantly elevated expression as compared with normal human melanocytes ([Figure 1](#f0005){ref-type="fig"}*A*). Next, we performed Gene Expression Omnibus (GEO) dataset analysis (GDS1989). Comparison of RICTOR mRNA levels in human nevi, non-metastatic and metastatic melanoma tissues showed significant up-regulation of RICTOR expression in metastatic melanoma tissues ([Figure 1](#f0005){ref-type="fig"}*B*). *In silico* analysis using the OncomineTM human cancer microarray database [@bb0150] revealed enhanced RICTOR mRNA levels in the \"invasive margin\" as compared to the \"tumor center\" of melanoma tissues ([Figure 1](#f0005){ref-type="fig"}*C*). The same dataset ("Roesch Melanoma" [@bb0185]) also showed elevated RICTOR expression levels according to the Clark levels V compared to IV with a tendency towards statistical significance ([Supplementary Figure 1](#ec0005){ref-type="supplementary-material"}*A*). Furthermore, RICTOR mRNA levels tended to be higher in "advanced stage" melanoma compared to "early stage" in the "Smith Skin" dataset [@bb0190] ([Supplementary Figure 1](#ec0005){ref-type="supplementary-material"}*B*), M1c-stage compared to M1b-stage in "Bogunovic Melanoma" dataset [@bb0195] ([Supplementary Figure 1](#ec0005){ref-type="supplementary-material"}*C*) and in metastatic melanoma compared to non-metastastic in "Haqq Melanoma" [@bb0200] ([Supplementary Figure 1](#ec0005){ref-type="supplementary-material"}*D*). Finally, RICTOR expression was detected in human melanoma liver metastases by immunohistochemical assessment ([Supplementary Figure 1](#ec0005){ref-type="supplementary-material"}*E*). In summary, these data indicate increased RICTOR expression in melanoma cells and tissues compared with normal melanocytes, non-tumorous skin and nevi, respectively. Further, RICTOR appears to be further enhanced in advanced melanoma stages including liver metastases, suggesting a role of RICTOR in melanoma progression and metastasis.

Analysis of Functional Effects of RICTOR Knock-Down in Melanoma Cells *In Vitro* {#s0085}
--------------------------------------------------------------------------------

To further analyze the effect of RICTOR in melanoma, we suppressed RICTOR expression in 3 different melanoma cells lines (MelIM, MelJU, B16) by siRNA. Efficacy of RICTOR knock-down by siRNA in cancer cell lines was assessed by Western blotting ([Figure 2](#f0010){ref-type="fig"}*A*). siRNA transfection led to an approximately 70-90% compared to cells transfected with scrambled RNA (ctrl. si), as determined by densitometry ([Figure 2](#f0010){ref-type="fig"}*B*). Next, we investigated the impact of RICTOR knock-down on growth of melanoma cell lines *in vitro.* After 48 hours, a slide but statistically significant impairment upon RICTOR knock-down was observed in MTT assays with human MelIM and MelJU cells ([Supplementary Figure 2](#ec0010){ref-type="supplementary-material"}, *A* and *B*). Similarly, murine B16 melanoma cells showed a significantly reduced signal already after 24 hours, while after 48 hours significant impairment was detected only with RICTOR si1 but not RICTOR si2 ([Figure 2](#f0010){ref-type="fig"}*C*). Additionally performed cell count analyses showed no reduction of cell number after 24 and 48 hours in MelIM, MelJU or B16 melanoma cells (data not shown). Since these results were not conclusive, we performed BrdU assay using B16 cells indicating no affection of tumor cell proliferation *in vitro* ([Figure 2](#f0010){ref-type="fig"}*D*). In contrast, analyses of melanoma cell motility upon RICTOR blockade by Boyden Chamber assays revealed significant impairment of constitutive tumor cell motility upon RICTOR knock-down after 24 hours in human MelIM and MelJU ([Figure 2](#f0010){ref-type="fig"}, *E* and *F*) as well as in murine B16 cells ([Figure 2](#f0010){ref-type="fig"}*G*). In summary, targeting RICTOR in melanoma cell lines limited effects on tumor growth and but significantly impairs tumor cell motility *in vitro*.

Inhibition of Hepatic Metastasis Formation *In Vivo* by Targeting RICTOR {#s0090}
------------------------------------------------------------------------

To assess our results regarding tumor cell motility *in vivo*, a syngeneic murine splenic injection liver metastasis model using B16 cells was applied. Ten days after tumor cell injection, macroscopically visible hepatic tumor load was significantly reduced in mice injected with RICTOR depleted B16 cells ([Figure 3](#f0015){ref-type="fig"}, *A* and *C*). The reduced tumor load was also reflected by a significantly lower total liver weight upon RICTOR knock-down ([Figure 3](#f0015){ref-type="fig"}*B*). Assessment of RICTOR expression in liver tissue showed no significant difference between the groups, although a trend towards reduced expression was found upon RICTOR knock-down ([Supplementary Figure 3](#ec0015){ref-type="supplementary-material"}*A*). However, PCR was performed with liver tissue but not microdissected liver metastases and, therefore, might not be significant. Nonetheless, our results indicate that targeting the mTORC2 component RICTOR in melanoma cells has the potential to reduce metastatic tumor growth in the liver.

For further and more precise evaluation of the effect of RICTOR knock-down on the hepatic tumor burden, livers were stained with H&E ([Figure 3](#f0015){ref-type="fig"}*D*). Interestingly, the microscopically detectable metastases as determined by tumor area/total liver area covered 47.6% in control livers but only 22% (RICTOR si1) and 29% (RICTOR si2) upon RICTOR knock-down, respectively ([Figure 3](#f0015){ref-type="fig"}*E*). This difference proved to be significant. In summary, our results indicate that targeting the mTORC2 component RICTOR has the potential to reduce hepatic metastasis of melanoma cells *in vivo*.Figure 4Modulation of HSC-induced motility and signaling via RICTOR blockade in melanoma cells.(A) aSMA staining reveals HSC surrounding liver metastases (bars = 100 μm).(B, C) Conditioned medium (CM) from HSC^hTERT^ (B) and LX2 (C) leads to a significant induction of MelIM motility after 24 hours (^\#^*P* \< .05 vs. untreated cells; bars=SEM). RICTOR knock-down in MelIM significantly reduced this effect (\**P* \< .05 vs. ctrl. si; bars=SEM).(D) CM from HSC^hTERT^ leads to a strong induction of pAKT^Ser473^ in MelIM melanoma cells, which is suppressed by RICTOR siRNA. Only minor effects of RICTOR inhibition are found on pAKT^Thr308^ phosphorylation.(E) Densitometry reveals up to a 60% reduction of AKT^Ser473^ phosphorylation.(F, G) Similar inhibitory effects on AKT phosphorylation are found, when MelIM cells are stimulated with CM from LX2.Figure 4Figure 5RICTOR blockade modulates (HSC-secreted)-HGF-induced motility and AKT phosphorylation.(A) HGF mRNA assessed by qRT-PCR shows more than 1000-fold higher mRNA expression in primary HSCs from two different donors (HSC-1 and HSC-2) compared to melanoma cell lines MelIM and MelJU.(B) HGF (50 ng/ml) significantly induces MelIM cell motility after 24 hours. Blockade of RICTOR in melanoma cells via siRNA approach abrogates this effect, as determined by Boyden Chamber assays. (^\#,^ \**P* \< .05 vs. ctrl. si; bars=SEM)(C) Similar results are found for MelJU.(D, E) In MelIM, HGF (50 ng/ml) leads to a marked increase of AKT^Ser473^ phosphorylation, while RICTOR blockade substantially reduces HGF-induced phosphorylation, as determined by Western blotting and subsequent densitometry.(F, G) Similar results regarding HGF-induced AKT^Ser473^ phosphorylation upon RICTOR inhibition are obtained for the MelJU melanoma cell line.Figure 5

Interaction Between HSC and Melanoma Cells Upon RICTOR Knock-Down {#s0095}
-----------------------------------------------------------------

The role of activated hepatic stellate cells in liver metastasis is increasingly recognized since these cells are also involved in forming a metastatic niche in the liver [@bb0085]. Interestingly, immunohistochemical staining for αSMA (a known marker for activated HSC) showed HSC surrounding melanoma metastases ([Figure 4](#f0020){ref-type="fig"}*A*) although no difference in αSMA and collagen-α1 mRNA expression was found between both groups ([Supplementary Figure 3](#ec0015){ref-type="supplementary-material"}, *B* and *C*). Nonetheless, we aimed to further analyze the interaction of HSC and melanoma cells with special emphasis on the role of RICTOR in tumor cells. To follow-up on this, motility of MelIM and MelJU upon RICTOR knock-down was determined using CM from HSC^hTERT^ and LX2 as chemoattractants. Results showed that CM from both HSC lines substantially increases tumor cell motility compared to controls ([Figure 4](#f0020){ref-type="fig"}, *B* and *C* and [Supplementary Figure 4](#ec0020){ref-type="supplementary-material"}, *A* and *B*). Blockade of the mTORC2 component RICTOR in melanoma cells significantly reduced CM-induced tumor cell migration ([Figure 4](#f0020){ref-type="fig"}, *B* and *C* and [Supplementary Figure 4](#ec0020){ref-type="supplementary-material"}, *A* and *B*). Since RICTOR/mTORC2 is the major regulator of AKT signaling, effects of RICTOR blockade on CM-induced AKT phosphorylation were subsequently investigated. Indeed, CM from HSC^hTERT^ and LX2 led to an induction of AKT^Ser473^ phosphorylation in MelIM cancer cells which was strongly reduced by inhibition of the mTORC2 component RICTOR ([Figure 4](#f0020){ref-type="fig"}, *D*--*G*). Similar results were obtained for MelJU (data not shown). In summary, CM from HSC induces motility and AKT^Ser473^ phosphorylation in melanoma cell lines, which can be effectively reduced by RICTOR depletion.

HGF is Mainly Secreted by HSCs and RICTOR Blockade Can Impair Its Effects on Motility and Signaling in Melanoma Cells {#s0100}
---------------------------------------------------------------------------------------------------------------------

In search for the factors secreted by HSC to explain our *in vitro* effects, we focused on HGF. HGF has previously been described as an important mediator of melanoma cell migration [@bb0115], [@bb0205], [@bb0210]. Interestingly, quantitative RT-PCR analysis revealed that HGF mRNA expression was more than 1000-fold higher in HSC compared with human melanoma cell lines ([Figure 5](#f0025){ref-type="fig"}*A*). Moreover, RICTOR blockade in melanoma cells *in vitro* does not modify HGF mRNA expression ([Supplementary Figure 5](#ec0025){ref-type="supplementary-material"}, *A* and *B*). This finding suggests that HSC are the main source of HGF in melanoma metastases and that HGF may also be a critical promoter of HSC-induced melanoma cell motility. To verify this hypothesis, we analyzed the effect HGF stimulation on motility and signaling in melanoma cell lines *in vitro*. Results demonstrate that HGF significantly increased motility of MelIM and MelJU cells ([Figure 5](#f0025){ref-type="fig"}, *B* and *C*). Importantly, RICTOR blockade in melanoma cell lines significantly impaired HGF-induced effect on tumor cell motility ([Figure 5](#f0025){ref-type="fig"}, *B* and *C*). Furthermore, incubation of both melanoma cell lines with HGF led to an induction of AKT^Ser473^ and AKT^Thr308^ phosphorylation. Upon RICTOR depletion, AKT^Ser473^ phosphorylation was impaired ([Figure 5](#f0025){ref-type="fig"}, *D*-*G*). In conclusion, our results demonstrate that (HSC secreted) HGF is a critical promoter for the recruitment of melanoma cells to the liver and that this effect is, at least in part, mediated *via* activation of mTORC2/RICTOR/AKT signaling.

Discussion {#s0105}
==========

Although novel therapeutic options have been successfully used for a proportion of melanoma patients, metastatic disease still has a poor prognosis. In case of liver metastases, 5-year overall survival is reported to be less than 10% [@bb0025], [@bb0215], [@bb0220]. In the present study we assess the essential mTORC2 component RICTOR as a potential target for anti-metastatic therapy in melanoma.

Results from our *in vitro* analyses using the *in silico* technique showed an increased expression of RICTOR mRNA in more advanced melanoma stages. Previously, Laugier *et al*. described that RICTOR overexpression enhanced melanocyte clonogenicity particularly upon *NRAS*-transformation. In addition, their study depicted RICTOR amplification as a frequent event in melanoma [@bb0065]. Furthermore, a recent report from Liang and coworkers delineated an overexpression of RICTOR in invasive melanoma upon evaluation by immunohistochemistry [@bb0075]. These results support our findings showing a higher RICTOR mRNA expression at the invasive margin. Even more, we found a significant increase of RICTOR in metastatic disease compared to pre-malignant nevi and an expression of RICTOR in resected melanoma liver metastases. Taken together, our results add further evidence to the fact that the mTORC2 component RICTOR is important for melanoma formation and progression.

From our *in vitro* analyses we found no effects of mTORC2/RICTOR inhibition on growth of melanoma cells This observation was not expected since Liang recently reported a significant inhibition of melanoma cell proliferation and cell cycle arrest in G2/M phase upon RICTOR blockade [@bb0075]. Additionally, growth inhibition by RICTOR blockade was also confirmed by others for gastric and colon cancer cells [@bb0225], [@bb0230]. In contrast, results from our previous study with pancreatic cancer cell lines also found only minor effects of RICTOR blockade on tumor cell growth *in vitro*, but a significant inhibition of tumor cell proliferation *in vivo* [@bb0055]. One might speculate that similar to pancreatic cancer, other pathways such as MAPK or WNT/ß-catenin are more important in regulating growth of melanoma cells [@bb0235], [@bb0240]. Finally, we found only minor constitutive phosphorylation of AKT on both phosphorylation sites (Ser473 and Thr308) and, concomitantly, only little effect of RICTOR blockade on constitutive AKT phosphorylation ([Figures 4](#f0020){ref-type="fig"}, *D* and *F*; Figure [5](#f0025){ref-type="fig"}, *D* and *F*). This might also explain the minor effects we observed on melanoma growth *in vitro*. Nonetheless, these results warrant further evaluation.

With regard to melanoma cell motility, we detected a significant inhibition of constitutive motility upon RICTOR blockade *in vitro*. These results are in line with previous reports that showed strongly impaired migration and invasion of melanoma cells after RICTOR inhibition *in vitro* [@bb0075]. Mechanistically, Gulhati *et al.* connected RICTOR-mediated impairment of colon cancer cell motility to effects on EMT and RhoA/Rac1 signaling [@bb0245]. In addition, Zhang *et al.* reported that RICTOR inhibition reduced the motility of breast cancer cell lines *via* effects on protein kinase Cζ (PKCζ) and F-actin binding protein cofilin [@bb0250]. Taken together, results from our study confirm the so far reported inhibitory effects of RICTOR blockade on tumor cell motility, supporting a potential role of RICTOR in cancer cell metastasis.

To further evaluate this issue we performed a syngeneic mouse splenic injection model. Our results showed a significant reduction of tumor burden in the liver upon siRNA-mediated RICTOR depletion. So far, a reduction of pulmonary metastasis from different breast cancer models has been described *via* effects on Rac1 and PRICKLE-RICTOR interaction upon mTORC2/RICTOR inhibition [@bb0255], [@bb0260]. Similar, Li *et al.* showed reduction of lung and bone metastasis in a mouse model of prostate cancer [@bb0265]. Regarding liver metastasis from human colon cancer, higher RICTOR mRNA and protein expression has been described compared to the primary tumor [@bb0245]. Recently, Sun *et al*. found no liver metastasis in a renal cell carcinoma xenograft model upon RICTOR knock-down [@bb0270]. The latter finding is in line with our previous study on pancreatic cancer, where a trend towards reduced liver metastasis was found [@bb0055]. However, we used a splenic injection model which harbors potential limitations such as the inability to represent the entire metastatic process and an artificial route to administer the tumor cells [@bb0275]. Nonetheless, the model is established for this issue and widely used [@bb0165], [@bb0275]. Moreover, our aim was to specifically target mTORC2/RICTOR in tumor cells in the metastatic process with can performed using the splenic injection model [@bb0280]. Finally, the present study is the first that addresses the issue of establishment of liver lesions with regard to mTORC2/RICTOR using a syngeneic melanoma mouse model *in vivo*. The latter further strengthens the results due to the existence of a functional immune system in the mice. In summary, these data strongly support our hypothesis for mTORC2/RICTOR being an important player in the development of melanoma metastasis in liver.

Since the hepatic environment has the potential to create a metastatic niche for cancer cells, we also addressed this issue. Staining for αSMA confirmed the previously described surrounding of liver metastases by HSC [@bb0210]. This is of particular importance since HSC are known drivers of hepatic tumor growth and metastasis formation [@bb0100], [@bb0115]. Therefore, we assessed the impact of CM from HSC on motility and AKT phosphorylation of melanoma cells with regard to mTORC2/RICTOR. Results from our experiments revealed that RICTOR inhibition efficiently impairs CM-induced motility and AKT^Ser473^ phosphorylation. These effects were further shown to be associated with HGF secreted by HSC, since similar results were detected when melanoma cells were stimulated with HGF. The rationale for this claim is based on our observation that HSC are the main source of HGF compared to melanoma cells and on recently published data showing the importance of the HSC -- HGF/c-MET signaling axis for invasion of hepatoma cells [@bb0205]. Moreover, we found no effects of mTORC2/RICTOR blockade on expression of HGF mRNA in melanoma cells *in vitro* and HGF mRNA in the liver *in vivo* ([Supplementary Figure 3](#ec0015){ref-type="supplementary-material"}*D*) which further supports our hypothesis that inhibition of RICTOR impairs HGF-induced signaling rather than HGF expression itself. However, HGF is not the exclusive mediator of HSC/tumor cell interaction. Indeed, several mechanisms have been described by which HSC can promote cancer metastasis including activation of the SDF1/CXCR4 axis and TGF-β/IQGAP-1 pathway [@bb0285], [@bb0290]. Moreover, the interaction between tumor cells and HSC seem to be more complex since we recently demonstrated that melanoma cells can induce proliferation and migration of HSC [@bb0125]. This is of particular importance with regard to potentially available therapies targeting mTORC2/RICTOR especially because little is currently known about the effect of RICTOR depletion in HSC. Finally, the interaction of HSC and tumor cells is only one part of the metastatic niche formation. Of course, other parts of the hepatic microenvironment, e.g. Kupffer cells or sinusoidal endothelial cells are important during the development of liver metastases (reviewed by [@bb0085]). So far, little is known neither about the role of mTORC2/RICTOR in these cells nor about the interaction with mTORC2/RICTOR inhibition in tumor cells. Nonetheless, to our knowledge this is the first report that describes the effect of mTORC2/RICTOR blockade in melanoma cells on CM from HSC.

In conclusion, the present study shows that RICTOR is associated with advanced disease in melanoma. In addition, we described for the first time that mTORC2/RICTOR inhibition in melanoma cells has the potential to reduce liver metastasis *in vivo* via effects on tumor cell motility. Furthermore, we found that mTORC2/RICTOR inhibition in melanoma cells significantly decreases the responsiveness of melanoma cells to HSC- and HGF-induced stimulation. Therefore, we provide evidence that targeting mTORC2/RICTOR is an interesting approach for anti-metastastic therapy in melanoma liver metastasis.

The following are the supplementary data related to this article.Supplementary Figure 1(A) RICTOR mRNA levels tended to be higher according to the Clark levels (IV: n=16; V: n=2). The data were obtained from the OncomineTM cancer microarray database using the dataset \"Roesch Melanoma\" (n=18 samples). (B) RICTOR mRNA levels in \"advanced stage\" (vertical growth phase melanoma, metastatic growth phase melanoma and melanoma positive lymph nodes, n=7) tended to be higher compared to \"early stage\" (benign nevi and melanoma *in situ*, n=6) tissue samples. The data were obtained from the OncomineTM cancer microarray database using the dataset \"Smith Skin\" (n=18 samples). (C) RICTOR mRNA expression in M1b-stage (N=3) as compared to M1c-stage tissues (N=2) from metastatic melanoma. A trend towards higher expression in M1c-stage was observed. The data were obtained from the OncomineTM cancer microarray database using the dataset \"Bogunovic Melanoma\" (n=44 samples). (D) RICTOR mRNA expression levels in melanoma tissue samples derived from primary (n=6) compared to metastatic (n=14) tumor sites. The data were obtained from the OncomineTM cancer microarray database using the dataset \"Haqq Melanoma\" (n=37 samples). (E) Cytoplasma positive staining for RICTOR. Furthermore, RICTOR demonstrates a strong positive staining in granulocytes.Supplementary Figure 1Supplementary Figure 2(A) MTT assay with MelIM showed a significantly reduced signal upon RICTOR inhibition after 48 hours (\**P* \< .05 vs. ctrl. Si; bars=SEM). (B) Similar, in MelJU RICTOR blockade led to reduced signal 48 hours (\**P* \< .05 vs. ctrl. Si; bars=SEM). However, growth inhibitory effects were not confirmed using the cell count assay (data not shown)Supplementary Figure 2Supplementary Figure 3(RT-PCR from liver tissue) (A) Only a trend towards reduced RICTOR mRNA expression was found in liver tissue 10 days after tumor cells inoculation. However, analysis was not performed with microdissected liver metastases which might explain the missing reduction. (B) Expression of αSMA mRNA in liver tissue did not differ between RICTOR knock-down groups and control *in vivo*. (C) Similar, no difference of collagen-α1 mRNA expression was found. (D) Analysis of HGF mRNA from liver tissue did not show a difference between control and RICTOR knock-down *in vivo*.Supplementary Figure 3Supplementary Figure 4(A) Conditioned medium (CM) from HSChTERT led to significant induction of MelJU motility after 24 hours (\#*P* \< .05 vs. untreated cells; bars=SEM). RICTOR knock-down in MelJU significantly reduced this effect (\**P* \< .05 vs. ctrl. Si; bars=SEM). (B) Similar results were obtained upon incubation of MelJU with CM from LX2 cells. Again, a significant induction of motility was found (\#*P* \< .05 vs. untreated cells; bars=SEM) which was significantly reduced by RICTOR knock-down (\**P* \< .05 vs. ctrl. Si; bars=SEM).Supplementary Figure 4Supplementary Figure 5(A) RICTOR blockade with siRNA has no effect on HGF mRNA expression in MelIM melanoma cells *in vitro*. (B) Similar results were obtained upon RICTOR blockade in MelJU cells.Supplementary Figure 5
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